SCHEMBL5355041

SCHEMBL5355041

CCCCCCCC(=O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@@H]1OC(=O)CCCCCCC

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HINT1 P49773 5/20 0.50
POLB P06746 1/20 0.49
F2 P00734 1/20 0.49
P2RY2 P41231 1/20 0.44
P2RY4 P51582 1/20 0.44
P2RY6 Q15077 1/20 0.44
GSK3A P49840 2/20 0.44
RPS6KA3 P51812 2/20 0.44
MAPK14 Q16539 2/20 0.44
FUT5 Q11128 1/20 0.43
POLA1 P09884 1/20 0.42
PNP P00491 1/20 0.42
KRAS P01116 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22875468 1.00 HINT1 (0.50) HINT1POLBF2P2RY2P2RY4
SCHEMBL8447610 1.00 HINT1 (0.50) HINT1POLBF2P2RY2P2RY4
SCHEMBL5352518 1.00 HINT1 (0.50) HINT1POLBF2P2RY2P2RY4
SCHEMBL9079838 0.93 HINT1 (0.53) HINT1POLBF2P2RY2P2RY4
SCHEMBL5351509 0.92 KDM4E (0.49) HINT1POLBFUT5POLA1KDM4E
SCHEMBL5351515 0.92 KDM4E (0.49) HINT1POLBFUT5POLA1KDM4E
SCHEMBL5357283 0.91 POLB (0.60) HINT1POLBF2P2RY2P2RY4
SCHEMBL5364897 0.91 POLB (0.60) HINT1POLBF2P2RY2P2RY4
SCHEMBL5352650 0.91 POLB (0.60) HINT1POLBF2P2RY2P2RY4
SCHEMBL5352210 0.91 POLB (0.60) HINT1POLBF2P2RY2P2RY4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307166-B1 Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis WELLSTAT THERAPEUTICS CORPORATION (US) 2007-12-11 US disclosed
US-20040235782-A1 Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis PRO-NEURON, INC. 2004-11-25 US disclosed
EP-1157698-A2 Treatment of inflammatory diseases with oxypurine nucleosides PRO-NEURON, INC. (US) 2001-11-28 EP disclosed
US-6060459-A Enhancing blood cell count with oxypurine nucleosides PRO-NEURON, INC. (US) 2000-05-09 US disclosed
US-6054441-A Antiinflammatory agents; treatment of bacterial, viral or fungal infections; autoimmune diseases PRO-NEURON, INC. (US) 2000-04-25 US disclosed
EP-0771204-A1 METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES PRO-NEURON, INC. (US) 1997-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235782-A1 Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis TPMT, NUDT1, ENTPD5 HINT1 117/4885POLB 799/4885F2 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.